Guillain-Barré syndrome in times of pandemics
- PMID: 32732383
- PMCID: PMC7509514
- DOI: 10.1136/jnnp-2020-324230
Guillain-Barré syndrome in times of pandemics
Keywords: guillain-barre syndrome; neurovirology; virology.
Conflict of interest statement
Competing interests: DRC has received consultancy honoraria from Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticalsc, Hansa Medical Ab, Pledpharma, Momenta Pharmaceuticals., CSL Behring, Sanofi-Aventis Recherche and Developpement, Pfizer Inc, Seattle Geneticsc, Octapharma Ag, Grifols, S.A., Cigna, Pharnext Sa, Annexon Biosciences, UCB Pharma, Boehringer Ingelheim, Biotest Pharmaceuticals., Argenx, Cytomx Therapeutics, Passagebio Pharma, Seattle Genetics, Astrazeneca Pharmaceuticals, Genentech, Merrimack Pharmaceuticals, Disarm Therapeutics, Levicept, Amgen. Johns Hopkins University has the rights to The Total Neuropathy Score for which DRC receives royalty payments.
Figures
References
-
- Muñoz LS, Barreras P, Lizarazo J, et al. . Neuroviruses emerging in the Americas study (NEAS): the Colombian experience during the 2016 outbreak of Zika virus infection (N4.002). Neurology 2017;88:N4.002.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical